Usfda

Rediff.com » News » Usfda

News for Usfda

News
Business

Covovax as Covid booster jab to be available on CoWIN soon

In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN......

India probes eye drop linked to vision loss in US

A day after its plant was inspected by Indian drug regulatory bodies over allegations that its eye drop was linked to vision loss in the United States, Tamil Nadu-based Global Pharma Healthcare has......

Why Is USFDA Inspecting India Pharma Firms?

Kindly note the image has been posted only for representational purposes.Photograph: Kind courtesy Pixabay.com The Indian pharmaceutical industry's recent tryst with the US drug regulator......

SIIto test Novavax's Omicron-specific vaccine

The Drugs Controller General of India has approved the manufacture of this Sars-CoV-2 spike protein recombinant nano-particle vaccine for ‘examination, test, and analysis’,......

Covovax nod to boost vaccination drive in India: SII

Vaccine major Serum Institute of India on Tuesday said the approval for the COVID-19 vaccine 'Covovax' would strengthen immunization initiatives across India and various lower and middle income......

Quality Lapses Shut Down Drug Makers

Most of the pharma units are failing in documentation, and validation processes, and many don't have full-fledged quality control laboratories. IMAGE: Kindly note the image has been posted only......

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. Illustration: Uttam......

'Depending on the product, the pricing pressure will always be there'

'From an Indian pharma sector's perspective, we are probably the only company that has a substantial presence in the specialty segment in the US and globally.' Photograph: Kind courtesy Sun Pharma......

Weak Q4 may be rare bitter pill for Sun Pharma

Sun Pharmaceutical Industries reported a 34 per cent year-on-year (Y-o-Y) jump in net profit to Rs 2,654.6 crore in Q4FY24. Photograph: Francis Mascarenhas/Reuters The company’s Ebitda......

'The formulations business been a growth driver'

'Fundamentally, we think that in the coming quarters, API business should come back.' Photograph: Kind courtesy Biocon Biocon is preparing to make the most of the peptides opportunity as these......

Rediff News

Usfda

News for Usfda

Covovax as Covid booster jab to be available on CoWIN soon

India probes eye drop linked to vision loss in US

Why Is USFDA Inspecting India Pharma Firms?

SIIto test Novavax's Omicron-specific vaccine

Covovax nod to boost vaccination drive in India: SII

Quality Lapses Shut Down Drug Makers

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

'Depending on the product, the pricing pressure will always be there'

Weak Q4 may be rare bitter pill for Sun Pharma

'The formulations business been a growth driver'

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS